OSHP Legislative Update Emails Repository
Email Date & Related Bills:
Our Legislative Affairs Division would like to make you aware of some important legislative updates regarding Ohio House Bill 451 and our organizations opposition to the practice of white bagging.
House Bill 451 (HB 451), also known as the “Revise Physician-Administered Drug Law” has been introduced to the Ohio House and referred to the House Insurance Committee. Although it has yet to be updated on the Ohio House of Representatives website/calendar, we have heard that the House Insurance Committee met this morning (2/9/22) at 9:30 am to hear testimony from proponents of HB 451.
HB 451, if enacted, would prohibit a health benefit plan from requiring that physician-administered drugs be dispensed by a pharmacy/affiliated pharmacy. Additionally, it would prohibit a plan from limiting coverage when such drugs are not dispensed by a pharmacy/affiliated pharmacy or covering such drugs with higher cost-sharing if dispensed in a setting other than a pharmacy.
OSHP SUPPORTS HB451 as the bill strongly aligns with our organizational opposition to the practice of white bagging.
We encourage our members to write to their legislators, especially those who sit on the house insurance committee and share your support for HB451. Your voice matters, legislators often mention that hearing the stories about how these practices impact our patients goes a long way toward earning their legislative support.
Additionally, whether or not your specific representatives are on the insurance committee, you can contact the chair of the insurance committee Thomas E. Brinkman by Clicking Here
Below you will find a variety of resources that will help you…
1. Familiarize yourself with white bagging and understand why OSHP opposes the practice
To learn more about our organizational position regarding the practice of white bagging, Click Here
2. Learn more about HB451
To learn more about House Bill 451: Click Here
For More Detailed Analysis: Click Here
For The Exact Legislative Text: Click Here
To watch the previous Insurance Committee Meeting Regarding HB451: Click Here
3.) Identify your Ohio representatives and those who sit on the house insurance committee.
To find your specific representatives: Click Here
To identify members of the House Insurance Committee: Click Here
If you have any questions/comments/concerns, please email me at firstname.lastname@example.org
Email Update: 2-17-2022: HB 218, HB 451, HB 122
There are 2 bills (HB218 and HB 451) that are currently in the hopper. Below is a brief review of the two bills.
House Bill 218 proposes that no school, or employer may require any vaccine/drug product that is not fully approved by the FDA, if a vaccine/other drug product has received full FDA approval, the bill establishes that natural immunity as well as reasons of personal conscience would exempt the student or employee from that requirement. The bill additionally prohibits any public or private entity to require proof of vaccination against COVID-19 for any reason and permits a court to aware attorney’s fees to that individual to support for the prohibition.
HB 218 was passed by the Ohio House on 11/18/21, it was later introduced in the Senate and referred to the General Government Budget Committee on 11/30/21. OSHP opposes HB218 and has worked with the council of colleges of pharmacy and other organizations to express our written opposition to the General Government Budget Committee.
House Bill 451 prohibits health benefit plans from requiring that a physician-administered medication be dispensed by an affiliated pharmacy and prohibits them from limiting coverage or altering the cost-sharing policy for the drugs in question if dispensed in a setting other than a pharmacy.
HB 451 was introduced to the Ohio house and referred to the Insurance committee on 10/13/21. OSHP supports HB451 and is working to draft written letters of support for the bill. OSHP members are encouraged to submit examples of how the practice of “white-bagging” has impacted you and your ability to care for your patients.
For the above, please submit these examples to email@example.com
House Bill 122 was officially signed into law on January 10, 2022. It made temporary telehealth flexibilities granted in Ohio under the COVID-19 public health emergency permanent. The timely passage of House Bill 122 ensured our healthcare professionals and patients could utilize telehealth seamlessly as the law went into effect before the temporary telehealth flexibilities expire on March 31, 2022. These changes will benefit patients and providers alike by increasing access to care and decreasing cost. We are excited to this piece of legislation come to fruition!
HB122 in summary:
Our Legislative Affairs Division would like to make you aware of some important legislative updates impacting our profession and our patients!
The MAT Act (H.R. 1384), which aims to remove the buprenorphine x-waiver requirements is going to be taken to a roll call vote for the energy and commerce committee’s meeting on Wednesday. The removal of the x-waiver is likely to improve the accessibility of medications for opioid use disorder, both here in Ohio and beyond. As a state, Ohio has voting representatives on this committee, Rep. Bob Latta (OH-5) and Rep. Bill Johnson (OH-6). At OSHP, our platform is supportive of the MAT act and its focus on increasing the accessibility of medications for opioid use disorder. You are encouraged to reach out to your representatives and encourage them to support The Mat Act (H.R. 1384) when it is up for a vote on May 18th. Below, you will find links to some resources from ASHP as well as some additionally resources created by the End Substance Use Disorder organization. These resources include email templates, call-in scripts, and general talking points that you will likely find helpful. The primary opposition to the bill relates to concerns about increased diversion if the x-waiver were to be eliminated, at the following link (Fact Sheet) you can find a fact sheet of DEA reports suggesting that removing the X-waiver may actually help reduce diversion. More information about ASHP’s efforts regarding the MAT act can be found here.
ASHP Email Templates: Take Action (aristotleactioncenter.com)
Other email templates: Email Template: MAT Act - May 2022
Call In Scripts: Call In Template: MAT Act - May 2022
General Talking Points: Talking Points
Evidence Based Reports by the DEA: MAT Act - Evidence on Diversion.pdf - Google Drive
Rep. Bob Latta (OH-5):
Health Staffer Email: firstname.lastname@example.org
Phone: Dial 202-224-3121 (ask the operator for the office of Bob Latta)
Rep. Bill Johnson (OH-6):
Health Staffer Email: email@example.com
Phone: Dial 202-224-3121 (ask the operator for the office of Bill Johnson)
Additionally, OSHP is tracking several bills that were recently introduced in The Ohio House Of Representatives. We encourage you to familiarize yourselves with the following bills that have been recently introduced. We will be watching these bills closely. If you would like to draft a letter of support or opposition to any of these bills for use by the general membership, please contact firstname.lastname@example.org
Bill Aims: To revise the law governing the review of patient information in the Ohio Automated Rx Reporting System, to establish requirements on the dispensing of opioid analgesics, and to provide for a cash transfer.
Full Text: HB652
Follow this bill: House Bill 652 | The Ohio Legislature
Bill Aims: To prohibit health insurers and pharmacy benefit managers from steering patients to affiliated pharmacies.
Full Text: HB655
Follow this bill: House Bill 655 | The Ohio Legislature
“Wow, thanks OSHP, is there anywhere that I can look to find this type of information outside of these email updates?”
You can find information regarding your representatives, as well as other bills that OSHP is tracking all on the OSHP website! Make sure to check out our brand-new advocacy page, it’s full of resources and information to help you become an effective advocate for change!
To check out our advocacy page and find your representatives: Click Here
If you have any questions, please contact email@example.com
Dan Arendt, PharmD, BCPS (he/him)
Division Director – Legislative Affairs
Ohio Society of Health-System Pharmacy (OSHP)